Fig. 3

Exosomal CLEC3B decreased VEGF in HCC cells to inhibit angiogenesis. a Enriched biological process of CLEC3B-correlated genes in GO Enrichment analysis. b The formation of tube-like structures was observed under bright field. Relative tube formation of ECs treated with supernatant from CLEC3B-overexpression (3B, P = 0.0265) or CLEC3B-down-regulated (3B-KD, P = 0.0225) HCC cells, and Sunitinib and supernatant from Exo-3B treated Huh-7 (no Sunitinib, P = 0.0053; Sunitinib, P = 0.9313; among groups, P < 0.0001) or Exo-3B-KD treated Bel-7402 (no Sunitinib, P = 0.0188; Sunitinib, P = 0.1518; among groups, P = 0.0006). The tube-like structures were determined by pixel density. c The representative images and statistic data of CD31 (B, P = 0.0005) and CD34 (C, P = 0.0065) in HCC of xenografts model. d VEGF levels in the supernatant from HCC cells with 3B (P < 0.0001) or 3B-KD (P = 0.039) and treated with Exo-3B (P = 0.0215) or Exo-3B-KD (P = 0.0229) determined by ELISA (pg/ml). e Representative images and the correlation between CLEC3B and VEGF in mouse liver orthotopic xenografts. f Representative images and the correlation between CLEC3B and VEGF (R = − 0.119, P = 0.231) in IHC analysis on human HCC tumor samples. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant